UNLABELLED: The function of peroxisome proliferator-activated receptor-gamma (PPARgamma) in hepatic inflammation and injury is unclear. In this study, we sought to determine the role of PPARgamma in hepatic ischemia/reperfusion injury in mice. Male mice were subjected to 90 minutes of partial hepatic ischemia followed by up to 8 hours of reperfusion. PPARgamma was found to be constitutively activated in hepatocytes but not in nonparenchymal cells. Upon induction of ischemia, hepatic PPARgamma activation rapidly decreased and remained suppressed throughout the 8-hour reperfusion period. This reduced activation was not a result of decreased protein availability as hepatic nuclear PPARgamma, retinoid X receptor-alpha (RXRalpha), and PPARgamma/RXRalpha heterodimer expression was maintained. Accompanying the decrease in PPARgamma activation was a decrease in the expression of the natural ligand 15-deoxy-Delta(12,14)-prostaglandin J(2). This was associated with reduced interaction of PPARgamma and the coactivator, p300. To determine whether PPARgamma activation is hepatoprotective during hepatic ischemia/reperfusion injury, mice were treated with the PPARgamma agonists, rosiglitazone and connecting peptide. These treatments increased PPARgamma activation and reduced liver injury compared to untreated mice. Furthermore, PPARgamma-deficient mice had more liver injury after ischemia/reperfusion than their wild-type counterparts. CONCLUSION: These data suggest that PPARgamma is an important endogenous regulator of, and potential therapeutic target for, ischemic liver injury.
UNLABELLED: The function of peroxisome proliferator-activated receptor-gamma (PPARgamma) in hepatic inflammation and injury is unclear. In this study, we sought to determine the role of PPARgamma in hepatic ischemia/reperfusion injury in mice. Male mice were subjected to 90 minutes of partial hepatic ischemia followed by up to 8 hours of reperfusion. PPARgamma was found to be constitutively activated in hepatocytes but not in nonparenchymal cells. Upon induction of ischemia, hepatic PPARgamma activation rapidly decreased and remained suppressed throughout the 8-hour reperfusion period. This reduced activation was not a result of decreased protein availability as hepatic nuclear PPARgamma, retinoid X receptor-alpha (RXRalpha), and PPARgamma/RXRalpha heterodimer expression was maintained. Accompanying the decrease in PPARgamma activation was a decrease in the expression of the natural ligand 15-deoxy-Delta(12,14)-prostaglandin J(2). This was associated with reduced interaction of PPARgamma and the coactivator, p300. To determine whether PPARgamma activation is hepatoprotective during hepatic ischemia/reperfusion injury, mice were treated with the PPARgamma agonists, rosiglitazone and connecting peptide. These treatments increased PPARgamma activation and reduced liver injury compared to untreated mice. Furthermore, PPARgamma-deficient mice had more liver injury after ischemia/reperfusion than their wild-type counterparts. CONCLUSION: These data suggest that PPARgamma is an important endogenous regulator of, and potential therapeutic target for, ischemic liver injury.
Authors: Gregory C Wilson; Christopher M Freeman; Joshua W Kuethe; Ralph C Quillin; Hiroyuki Nojima; Rebecca Schuster; John Blanchard; Michael J Edwards; Charles C Caldwell; Alex B Lentsch Journal: Am J Physiol Gastrointest Liver Physiol Date: 2015-02-26 Impact factor: 4.052
Authors: Catherine M T Sherwin; Lili Ding; Jennifer Kaplan; Michael G Spigarelli; Alexander A Vinks Journal: J Pharmacokinet Pharmacodyn Date: 2011-06-11 Impact factor: 2.745
Authors: Sebastian Doll; Bettina Proneth; Yulia Y Tyurina; Elena Panzilius; Sho Kobayashi; Irina Ingold; Martin Irmler; Johannes Beckers; Michaela Aichler; Axel Walch; Holger Prokisch; Dietrich Trümbach; Gaowei Mao; Feng Qu; Hulya Bayir; Joachim Füllekrug; Christina H Scheel; Wolfgang Wurst; Joel A Schick; Valerian E Kagan; José Pedro Friedmann Angeli; Marcus Conrad Journal: Nat Chem Biol Date: 2016-11-14 Impact factor: 15.040
Authors: Rebecca D Edmonds; Yoram Vodovotz; Claudio Lagoa; Joyeeta Dutta-Moscato; Yawching Yang; Mitchell P Fink; Ryan M Levy; Jose M Prince; David J Kaczorowski; George C Tseng; Timothy R Billiar Journal: Physiol Genomics Date: 2011-08-09 Impact factor: 3.107
Authors: Laura Zanobbio; Marco Palazzo; Silvia Gariboldi; Giuseppina F Dusio; Diego Cardani; Valentina Mauro; Fabrizio Marcucci; Andrea Balsari; Cristiano Rumio Journal: Am J Pathol Date: 2009-08-21 Impact factor: 4.307
Authors: Satoshi Kuboki; Thomas Shin; Nadine Huber; Thorsten Eismann; Elizabeth Galloway; Rebecca Schuster; John Blanchard; Michael J Edwards; Alex B Lentsch Journal: Hepatology Date: 2008-10 Impact factor: 17.425